Gregg Feinerman, MD
Ophthalmology · Newport Beach, CANPI 1649214826
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (55.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Carl Zeiss Meditec Digital Innovations LLC at 55.5% of the total. Reporting peaked in 2024 at $7,428 and has fallen 89.0% since, to $816 in 2025.
Across 165 payments — averaging $66.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec Digital Innovations LLC$6K
- Alcon$934
- Carl Zeiss Meditec USA, Inc.$860
- Bausch & Lomb Americas Inc.$765
- AbbVie$434
- Rxsight Inc$205
- plus $2K from 19 others
Across 37 payments — averaging $5934.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$150K
- Rxsight Inc$68K
- Bausch & Lomb Americas Inc.$2K
What the payments were for
- Consulting fees$430%
- Speaking & faculty fees$260%
- Travel & lodging$2582%
- Food & beverage$4,50641%
- Gifts$190%
- Other$6,05956%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec Digital Innovations LLC | 1 | $6,059 |
| Alcon | 38 | $934 |
| Carl Zeiss Meditec USA, Inc. | 7 | $860 |
| Bausch & Lomb Americas Inc. | 24 | $765 |
| AbbVie(2 entities) | 26 | $434 |
| Rxsight Inc | 5 | $205 |
| Tarsus Pharmaceuticals, Inc. | 4 | $199 |
| Shire North American Group Inc | 10 | $184 |
| Novartis | 8 | $177 |
| Sun Pharmaceutical Industries Inc. | 6 | $160 |
| Kala Pharmaceuticals, Inc. | 6 | $133 |
| Carl Zeiss Meditec, Inc. | 2 | $130 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $99 |
| Harrow Eye, LLC | 4 | $99 |
| Glaukos Corporation | 3 | $87 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $73 |
| Alcon Research LLC | 2 | $59 |
| Oyster Point Pharma, Inc. | 2 | $55 |
| Bausch Health US, LLC | 1 | $43 |
| Ocular Therapeutix, Inc. | 2 | $42 |
| Thea Pharma Inc. | 2 | $41 |
| Eyevance Pharmaceuticals LLC | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Staar Surgical Company | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,912 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 61 | $57,177 |
| XiidraLifitegrast | 15 | $20,106 |
| LumiganBimatoprost | 28 | $16,795 |
| Prednisolone Acetate | 367 | $10,853 |
| Alphagan PBrimonidine Tartrate | 24 | $10,467 |
| MieboPerfluorohexyloctane/Pf | 12 | $8,650 |
| Brimonidine Tartrate | 122 | $7,930 |
| Latanoprost | 499 | $6,642 |
| Bromfenac Sodium | 50 | $5,901 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $5,449 |
| Travoprost | 30 | $5,142 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 34 | $4,048 |
| ProlensaBromfenac Sodium | 11 | $3,976 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $3,066 |
| Brinzolamide | 18 | $2,901 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $434 | $89,887129 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $765 | $31,53638 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $73 | $3,97611 claims |
| AlconSimbrinza | $934 | $3,06612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Newport Beach
- Sheri RowenNewport Beach$1M
- Ehsan SadriNewport Beach$255K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.